The Next Frontier In Precision Oncology: Why sex and gender must be recognised as the foundations of Precision Oncology

Precision oncology has transformed cancer care, enabling clinicians to match patients with treatments based on the molecular characteristics of their tumours. Yet two critical drivers of variation between patients — sex and gender — remain inconsistently integrated into oncology research, clinical trials and care.

Madano’s latest report, The Next Frontier in Precision Oncology – Why sex and gender must be recognised as the foundations of Precision Oncology, examines how overlooking sex and gender creates evidence gaps that affect treatment safety, effectiveness and patient outcomes. Drawing on insights from oncology experts, patient advocates and journalists, the report explores where structural bias enters drug development, trial design and reporting.

It also highlights the growing momentum behind sex and gender informed precision medicine and outlines the coordinated action needed from industry, regulators and researchers to ensure cancer care reflects the full biological and social reality of patients.

[Download now]

If you would like to discuss how we can work together to advance this agenda, or learn more about our expertise in oncology, please get in touch via [email protected].